Methods for slowing familial ALS disease progression
View Patent ↗Methods for slowing disease progression in an individual suffering from familial ALS are provided. Also provided are methods of increasing the survival time of an individual suffering from familial ALS. These methods employ antisense oligonucleotides targeted to SOD1, for use in inhibiting the expression of SOD1 in the central nervous system of an individual suffering from familial ALS.
1. A method of treating amyotrophic lateral sclerosis (ALS) comprising administering to the cerebrospinal fluid of a subject in need thereof a therapeutically or prophylactically effective amount of a composition comprising:
a modified oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase sequence comprising an 8-nucleobase portion of SEQ ID NO: 3, wherein the modified oligonucleotide is specifically hybridizable with SEQ ID NO: 1, and
a pharmaceutically acceptable diluent or carrier.
2. The method of claim 1 , wherein administering is intrathecal administration.
3. The method of claim 1 , wherein administering is intraventricular administration.
4. The method of claim 1 , wherein at least one intenucleoside linkage is a phosphorothioate internucleoside linkage.
5. The method of claim 1 , wherein at least one nucleoside comprises a modified sugar.
6. The method of claim 5 , wherein the modified sugar is a 2′-O-methoxyethyl.
7. The method of claim 1 , wherein at least one nucleoside comprises a modified nucleobase.
8. The method of claim 7 , wherein the modified nucleobase is a 5-methylcytosine.
9. The method of claim 1 , wherein the modified oligonucleotide comprises:
a gap segment consisting of linked deoxynucleosides;
a 5′ wing segment consisting of linked nucleosides;
a 3′ wing segment consisting of linked nucleosides;
wherein the gap segment is position between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.
10. The method of claim 9 , wherein the modified oligonucleotide comprises:
a gap segment consisting often linked deoxynucleosides;
a 5′ wing segment consisting of five linked nucleosides;
a 3′ wing segment consisting of five linked nucleosides;
wherein the gap segment is position between the 5′ wing segment and the 3′ wing segment, wherein each nucleoside of each wing segment comprises a 2′-O-methoxyethyl sugar; wherein each cytosine is a 5′ methylcytosine, and wherein each internucleoside linkage is a phosphorothioate linkage.
11. A method of treating amyotrophic lateral sclerosis (ALS) comprising administering to the cerebrospinal fluid of a subject in need thereof a therapeutically or prophylactically effective amount of a composition comprising:
a modified oligonucleotide consisting of 12 to 30 linked nucleosides having a nucleobase sequence comprising an 8-nucleobase portion of SEQ ID NO: 3, wherein the modified oligonucleotide is 100% complementary to SEQ ID NO: 1, and
a pharmaceutically acceptable diluent or carrier.
12. The method of claim 11 , wherein administering is intrathecal administration.
13. The method of claim 11 , wherein administering is intraventricular administration.
14. The method of claim 11 , wherein at least one intenucleoside linkage is a phosphorothioate intenucleoside linkage.
15. The method of claim 11 , wherein at least one nucleoside comprises a modified sugar.
16. The method of claim 15 , wherein the modified sugar is a 2′-O-methoxyethyl.
17. The method of claim 11 , wherein at least one nucleoside comprises a modified nucleobase.
18. The method of claim 17 , wherein the modified nucleobase is a 5-methylcytosine.
19. The method of claim 11 , wherein the modified oligonucleotide comprises:
a gap segment consisting of linked deoxynucleosides;
a 5′ wing segment consisting of linked nucleosides;
a 3′ wing segment consisting of linked nucleosides;
wherein the gap segment is position between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.
20. The method of claim 19 , wherein the modified oligonucleotide comprises:
a gap segment consisting often linked deoxynucleosides;
a 5′ wing segment consisting of five linked nucleosides;
a 3′ wing segment consisting of five linked nucleosides;
wherein the gap segment is position between the 5′ wing segment and the 3′ wing segment, wherein each nucleoside of each wing segment comprises a 2′-O-methoxyethyl sugar; wherein each cytosine is a 5′ methylcytosine, and wherein each internucleoside linkage is a phosphorothioate linkage.